218 related articles for article (PubMed ID: 26159518)
1. Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays.
Tan BX; Brown CJ; Ferrer FJ; Yuen TY; Quah ST; Chan BH; Jansson AE; Teo HL; Nordlund P; Lane DP
Sci Rep; 2015 Jul; 5():12116. PubMed ID: 26159518
[TBL] [Abstract][Full Text] [Related]
2. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
3. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2017; 12(12):e0189379. PubMed ID: 29228061
[TBL] [Abstract][Full Text] [Related]
5. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
7. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
8. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
9. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting.
Wachter F; Morgan AM; Godes M; Mourtada R; Bird GH; Walensky LD
Oncogene; 2017 Apr; 36(15):2184-2190. PubMed ID: 27721413
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
12. MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance.
Moscetti I; Teveroni E; Moretti F; Bizzarri AR; Cannistraro S
Int J Nanomedicine; 2016; 11():4221-9. PubMed ID: 27621617
[TBL] [Abstract][Full Text] [Related]
13. A critical assessment of the synthesis and biological activity of p53/human double minute 2-stapled peptide inhibitors.
Wallbrecher R; Chène P; Ruetz S; Stachyra T; Vorherr T; Brock R
Br J Pharmacol; 2017 Aug; 174(16):2613-2622. PubMed ID: 28436014
[TBL] [Abstract][Full Text] [Related]
14. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein.
Joseph TL; Lane D; Verma CS
Cell Cycle; 2010 Nov; 9(22):4560-8. PubMed ID: 21088491
[TBL] [Abstract][Full Text] [Related]
15. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
16. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.
Wei SJ; Chee S; Yurlova L; Lane D; Verma C; Brown C; Ghadessy F
Oncotarget; 2016 May; 7(22):32232-46. PubMed ID: 27057630
[TBL] [Abstract][Full Text] [Related]
17. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
[TBL] [Abstract][Full Text] [Related]
18. Structure of the stapled p53 peptide bound to Mdm2.
Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
[TBL] [Abstract][Full Text] [Related]
19. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
[TBL] [Abstract][Full Text] [Related]
20. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
